Zealand Pharma, a Copenhagen-based biotech company, is establishing a major research hub in Cambridge, Massachusetts, to accelerate drug discovery by merging its decades of peptide expertise with artificial intelligence and machine learning tools. The facility, opening in September 2026, represents a strategic shift toward using AI-driven automation and next-generation molecule design to move medicines from lab concept to clinical trials faster. What Is Zealand Pharma Trying to Accomplish? Zealand Pharma has spent more than 25 years perfecting the science of peptides, which are short chains of amino acids that can act as powerful drugs. The company has already brought two products to market and has three candidates in late-stage development. But the biotech landscape is changing rapidly, and the company recognizes that AI and automation are becoming essential tools for staying competitive in drug discovery. The new Cambridge hub is designed to do more than just expand office space. It will serve as a dedicated research facility where Zealand Pharma can tap into Boston's thriving biotech ecosystem, which includes over 600 life sciences companies and world-class academic institutions. The location at 35 CambridgePark Drive is a purpose-built laboratory property owned by Healthpeak, a real estate investment trust focused on life sciences facilities. "The Cambridge hub is a tangible commitment and an important addition to our research footprint, complementing the strong and active research already taking place in Denmark and marking another important step in our ambition to become a leader in obesity and metabolic health," said Adam Steensberg, President and Chief Executive Officer of Zealand Pharma. Adam Steensberg, President and Chief Executive Officer of Zealand Pharma How Will AI and Automation Change Drug Discovery at the Hub? - AI-Driven Molecule Design: The Cambridge facility will use artificial intelligence and machine learning models to design new drug molecules more efficiently, reducing the time it takes to identify promising candidates for testing. - Advanced Automation: Automated systems will handle repetitive laboratory tasks, allowing researchers to focus on higher-level scientific questions and accelerate the translation of scientific insights into actual medicines. - Hybrid Modality Expansion: Beyond peptides, the hub will develop antibody-peptide conjugates (APCs) and small interfering RNAs (siRNAs), which are different types of molecules that can target specific tissues more precisely. The strategic value of this expansion lies in combining two distinct scientific traditions. Denmark has been the home of Zealand Pharma's peptide research for nearly three decades, while Cambridge offers access to cutting-edge AI, machine learning, and automation expertise. This geographic split allows the company to leverage the best talent and infrastructure from both regions. "Cambridge, Massachusetts is one of the world's great engines of biotech innovation, and we are excited to build our research hub where the metabolic expertise of Denmark and multi-modal platform capabilities from Cambridge can come together. This hub will deepen our discovery capabilities for medicine creation and help us move from idea to clinic faster," explained Utpal Singh, Chief Scientific Officer of Zealand Pharma. Utpal Singh, Chief Scientific Officer of Zealand Pharma Why Does Location Matter for AI-Powered Drug Discovery? The decision to establish a hub in Cambridge reflects a broader trend in biotech: proximity to talent, partnerships, and infrastructure accelerates innovation. Boston's life sciences ecosystem is home to leading universities, research hospitals, and biotech companies that are actively working on AI applications in medicine. By locating in Cambridge, Zealand Pharma gains immediate access to collaborators, potential hires with expertise in machine learning and computational biology, and partnerships with local organizations developing AI and automation tools. The company is actively recruiting for the Cambridge site, signaling that it plans to build a substantial team there. The facility will include not just research laboratories but also office space, meeting rooms, and collaborative areas designed to foster innovation and cross-functional teamwork. This infrastructure supports Zealand Pharma's broader strategy, known as "Metabolic Frontier 2030," which aims to expand the company's research platform beyond its core peptide expertise into new therapeutic modalities. For patients and the pharmaceutical industry, the implications are significant. Faster drug discovery means new treatments for obesity and metabolic diseases could reach patients sooner. AI-driven approaches can identify promising drug candidates that human researchers might miss, and automation reduces the time spent on routine laboratory work. The combination of Denmark's peptide expertise and Cambridge's AI capabilities positions Zealand Pharma to compete effectively in a rapidly evolving market where artificial intelligence is becoming a critical competitive advantage. The Cambridge hub represents more than just a real estate decision; it signals that even established biotech companies with decades of expertise recognize that AI and machine learning are essential tools for the future of drug discovery. As Zealand Pharma scales its operations and expands its research platform, the company is betting that the intersection of traditional pharmaceutical science and modern AI will unlock new possibilities for treating metabolic diseases.
